Tevogen Bio’s Founding CEO, Ryan Saadi, Expresses Conviction in Company’s Growth Strategy and Reaffirms Newly Effective Form S-1 Does Not Relate to Previously Undisclosed New Issuance of Dilutive Securities Tevogen Bio reaffirms that the registration statement does not relate to any previously undisclosed new issuances of dilutive securities.

Tevogen Bio’s R&D Leadership Discusses The Promise of Its Genetically Unmodified, Off-The-Shelf T Cell Technology For The Treatment of Infectious Diseases, Cancers, and Neurological Disorders With Nasdaq's Kristina Ayanian Dr. Flomenberg and Dr. Grosso are leading experts in T cell biology and its clinical applicationsTevogen’s ExacTcell™ platform is designed to address current cost, and patient accessibility...